A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: clinical and immunological data

Authors

Mansoor Saleh, Aga Khan UniversityFollow
Albert LoBuglio, University Of Alabama At Birmingham, USA
Richard Wheeler, University Of Alabama At Birmingham, USA
Kimberly Rogers, University Of Alabama At Birmingham, USA
Amy Haynes, University Of Alabama At Birmingham, USA
Jeannette Lee, University Of Alabama At Birmingham, USA
M B. Khazaeli, University Of Alabama At Birmingham, USA

Document Type

Article

Department

Haematology and Oncology, East Africa

Abstract

A group of 15 patients with metastatic colorectal adenocarcinoma received a combination of interferon γ (0.1 mg/m², days 1–15) and the murine monoclonal antibody 17-1A (400 mg, days 5, 7, 9 and 12). The treatment was tolerated with minimal toxicity. Of the 14 evaluable patients, 13 developed human antibody to murine 17-1A, with 11 patients demonstrating antibody to the variable region of 17-1A (anti-idiotype). Antibody to the variable region was inhibited by 17-1A but not by mouse immunoglobulin. Sera from patients with substantial anti-idiotype reactivity were capable of inhibiting the binding of murine 17-1A to antigen expressing LS174-T cells thus indicating the presence of antibody directed against the 17-1A combining site (mirror-image anti-idiotype). The median survival of the whole group was 56 weeks and there was no correlation between clinical response/survival and the development of anti-idiotype antibody.

Comments

This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Cancer Immunology, Immunotherapy

DOI

https://doi.org/ 10.1007/BF01771455

Recommended Citation

Saleh, M., LoBuglio, A., Wheeler, R., Rogers, K., Haynes, A., Lee, J., Khazaeli, M. B. (1990). A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: clinical and immunological data. Cancer Immunology, Immunotherapy, 32(3), 185-190.
Available at: https://ecommons.aku.edu/eastafrica_fhs_mc_haematol_oncol/153